188 related articles for article (PubMed ID: 30565896)
1. The utility of combined mutation analysis and microRNA classification in reclassifying cancer risk of cytologically indeterminate thyroid nodules.
Banizs AB; Silverman JF
Diagn Cytopathol; 2019 Apr; 47(4):268-274. PubMed ID: 30565896
[TBL] [Abstract][Full Text] [Related]
2. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
3. Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology.
Mehta RS; Carty SE; Ohori NP; Hodak SP; Coyne C; LeBeau SO; Tublin ME; Stang MT; Johnson JT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
Surgery; 2013 Oct; 154(4):730-6; discussion 736-8. PubMed ID: 24074409
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
5. Outcome of thyroid nodules characterized as atypia of undetermined significance or follicular lesion of undetermined significance and correlation with Ultrasound features and BRAF(V600E) mutation analysis.
Jeong SH; Hong HS; Lee EH; Cha JG; Park JS; Kwak JJ
AJR Am J Roentgenol; 2013 Dec; 201(6):W854-60. PubMed ID: 24261392
[TBL] [Abstract][Full Text] [Related]
6. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
Wu H; Zhang B; Cai G; Li J; Gu X
PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
[TBL] [Abstract][Full Text] [Related]
7. Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules.
Sistrunk JW; Shifrin A; Frager M; Bardales RH; Thomas J; Fishman N; Goldberg P; Guttler R; Grant E
J Am Soc Cytopathol; 2020; 9(4):232-241. PubMed ID: 32247769
[TBL] [Abstract][Full Text] [Related]
8. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
[TBL] [Abstract][Full Text] [Related]
9. Rethinking Malignancy Risk in Indeterminate Thyroid Nodules with Positive Molecular Studies: Southern California Permanente Experience.
Cohen DS; Tongson-Ignacio JE; Lolachi CM; Ghaderi VS; Jahan-Parwar B; Thompson LDR
Otolaryngol Head Neck Surg; 2019 Sep; 161(3):419-423. PubMed ID: 31013183
[TBL] [Abstract][Full Text] [Related]
10. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
Rosario PW
Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
[TBL] [Abstract][Full Text] [Related]
11. RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAFV600E Mutation-Negative Nodules?
Yoon JH; Kwon HJ; Lee HS; Kim EK; Moon HJ; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(27):e1084. PubMed ID: 26166089
[TBL] [Abstract][Full Text] [Related]
12. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients.
Arva NC; Deitch SG
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):753-60. PubMed ID: 25879311
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Clinical Usefulness of BRAFV600E Mutation Analysis of Core-Needle Biopsy Specimens in Thyroid Nodules with Previous Atypia of Undetermined Significance or Follicular Lesions of Undetermined Significance Results.
Choi SH; Baek JH; Lee JH; Choi YJ; Song DE; Chung KW; Kim TY; Shong YK
Thyroid; 2015 Aug; 25(8):897-903. PubMed ID: 25978151
[TBL] [Abstract][Full Text] [Related]
15. AACE/ACE disease state commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology.
Bernet V; Hupart KH; Parangi S; Woeber KA
Endocr Pract; 2014 Apr; 20(4):360-3. PubMed ID: 24727662
[TBL] [Abstract][Full Text] [Related]
16. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
17. Incremental utility of expanded mutation panel when used in combination with microRNA classification in indeterminate thyroid nodules.
Jackson S; Kumar G; Banizs AB; Toney N; Silverman JF; Narick CM; Finkelstein SD
Diagn Cytopathol; 2020 Jan; 48(1):43-52. PubMed ID: 31675178
[TBL] [Abstract][Full Text] [Related]
18. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
19. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
Kiernan CM; Solórzano CC
J Am Coll Surg; 2017 Jul; 225(1):77-82. PubMed ID: 28223197
[TBL] [Abstract][Full Text] [Related]
20. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
